Human T-cell leukemia virus type I (HTLV-I) transcription generally depends on the ability of the viral Tax protein to bind the CREB transcription factor and form an active complex by recruiting CBP/p300 coactivators to the long terminal repeat (LTR). Studies have demonstrated that T-cell activating agents that stimulate CREB are potent inducers of HTLV-I transcription. Herein, we demonstrate that bpV[pic], a protein tyrosine phosphatase (PTP) inhibitor activates the HTLV-I LTR in the presence and absence of Tax expression. Optimal activation occurred at 8 h and was synergistic with forskolin or PGE 2 . Infected cell lines and cells transfected with HTLV-I proviral DNA were equally responsive to the synergistic effect of bpV and forskolin on HTLV-I gene expression. Activation of the LTR by bpV[pic] was T-cell receptor-independent, but required ZAP70, calcineurin activity and functional calcium entry. Inhibition of the SHP-1 PTP was suggested to be important. Transfection experiments with a CREB dominant-negative mutant and with isolated TRE1-or CREB-responsive reporter constructs and treatment with the MDL-12,330A adenylate cyclase inhibitor all supported the involvement of a CREB/ATF family member in this bpVdependent activation of the HTLV-I LTR, although CREB itself did not seem to be involved. Analysis of HTLV-I reporter constructs containing mutated CREB-binding sites also implied the involvement of another element in this activation. These results demonstrate for the first time a powerful effect of PTP inhibitors on HTLV-I LTR activity and suggest participation of both CREB-dependent and -independent pathways in this activation. D 2004 Elsevier Inc. All rights reserved.
Introduction
Human T-cell leukemia virus type I (HTLV-I) is the etiological agent of adult T-cell leukemia/lymphoma (ATLL) (Hinuma et al., 1981; Poiesz et al., 1980; Yoshida et al., 1982) and the neurological disease HTLV-I-associated myelopathy (also termed tropical spastic paraparesis) (HAM/TSP) (Gessain et al., 1985; Osame et al., 1986; Rodgers-Johnson et al., 1985) . A number of other diseases have been tentatively linked to HTLV-I infection in humans although their association remains to be more clearly ascertained (Uchiyama, 1997) . HTLV-I is endemic in specific regions of the world including Japan and the Caribbean Islands. Between 10 and 20 million individuals are presently infected with HTLV-I; however, only 5% of these infected individuals will eventually develop HTLV-Irelated diseases, while the rest will remain asymptomatic for life (Uchiyama, 1997) .
Infected cells are generally considered to be poor producers of viral particles and only a very low proportion of virions are infectious (Sommerfelt, 1999) . It is thus believed that HTLV-I replication in infected patients occurs mainly through mitotic cell division, resulting in an oligoclonal expansion of infected cells. The viral Tax protein is an important T-cell proliferation factor thereby contributing to the expansion of infected cells (for review, see Smith and Greene, 1991; Yoshida et al., 1995) . However, when uninfected individuals become infected, a transient burst of viral gene expression from the infected cells promotes cell-to-cell transmission of HTLV-I, and might be part of the two-step infection process previously described in the squirrel monkey model (Kazanji et al., 2000) . Following the hypothesized cell contact-mediated increase in viral gene expression, HTLV-I transcription is believed to be mostly silent in the infected individual, which might be important for allowing efficient immune escape.
Like all retroviruses, HTLV-I is bordered by sequences known as long terminal repeats (LTRs). The 5V LTR contains the major viral promoter and thus controls the expression of HTLV-I genes. Several regions of the promoter have been identified as important regulators of HTLV-I gene expression. Perhaps, the best-characterized transcriptional control elements within the HTLV-I promoter are the Tax-responsive element 1 (TRE1) sequences, which mediate the powerful transactivation potential of Tax (Fujisawa et al., 1986; Paskalis et al., 1986; Shimotohno et al., 1986) . The three imperfect TRE1 repeats span the U3 region of the LTR and contain suboptimal cyclic AMP response element binding protein (CREB) binding sites. Tax is thought to stabilize the association of both CREB and CREB-binding protein (CBP)/ p300 with the LTR, thereby mediating its strong activation of HTLV-I gene expression (Giebler et al., 1997; Harrod et al., 1998; Kashanchi et al., 1998; Kwok et al., 1996; Yan et al., 1998) . Additional studies have also identified a second Taxresponsive element within the LTR, TRE2 (Brady et al., 1987) , which contains sequences specific for the binding of transcription factors such as NF-nB and Ets-1 (Bosselut et al., 1990; Gitlin et al., 1991; Numata et al., 1991) .
Little is known about regulation of the HTLV-I LTR in the absence of Tax. This regulation is important in vivo since Tax expression is generally low in HTLV-I-positive cells isolated from infected individuals (Brauweiler et al., 1995) . A previous study has suggested that some of the TRE1 repeats are important for basal transcription (Barnhart et al., 1997) . These same sequences are also known to be important determinants for HTLV-I LTR activation by cAMP-modulating agents such as forskolin (Nakamura et al., 1989; Poteat et al., 1989) . In contrast, agents that induce T-cell receptor (TCR) aggregation have been shown to be poor activators of the HTLV-I promoter (Copeland et al., 1994 (Copeland et al., , 1995 . A phorbol 12-myristate 13-acetate (PMA)-responsive element has been identified within the HTLV-I promoter and its modulatory activity is mediated through Sp1 and p53 (Torgeman et al., 1999 (Torgeman et al., , 2001b . However, activation of the LTR in response to PMA was shown to depend on the apoptotic-inducing effects of PMA as well as other apoptosis-inducing agents rather than transcriptional effects (Torgeman et al., 2001a) . A study by Lin et al. (1998) demonstrated that phytohemagglutinin (PHA)/PMA in combination with Tax resulted in high levels of HTLV-I replication and that this induction was sensitive to inhibitors of tyrosine phosphorylation.
Tyrosine phosphorylation is a very important event in intracellular signaling cascades. In fact, early events following T cell activation involve a sustained increase in intracellular phosphotyrosine levels. A critical balance between the activity of protein tyrosine kinases (PTK) and protein tyrosine phosphatases (PTP) maintains a crucial intracellular balance of tyrosine phosphorylation (Yakura, 1998) . Some of the most important PTKs for T-cell activation are p56 lck , p59 fyn , and ZAP70, while important PTPs in T-cell activation include SHP-1, a downregulator of T cell activation, and CD45, an abundant molecule having both negative and positive effects on T-cell receptormediated signaling (Yakura, 1998) . Specific PTP inhibitors have been used to examine the role of PTPs in T cell activation. Evidence clearly suggests that these inhibitors are potent T-cell activators, and strongly induce IL-2 secretion and the activity of transcription factors such as AP-1 and NF-nB (Barbeau et al., 1997; Imbert et al., 1994 Imbert et al., , 1996a Imbert et al., , 1996b Ouellet et al., 1999 Ouellet et al., , 2003a Ouellet et al., , 2003b Secrist et al., 1993) . Recently, we demonstrated that PTP inhibitors are also powerful activators of NFAT (Fortin et al., 2001) .
Based on the results of Lin et al. (1998) , we wanted to determine whether PTP could modulate transcriptional activity of the HTLV-I LTR. To directly test this hypothesis, we used powerful PTP inhibitors known as bis-peroxovanadium (bpV) compounds (Posner et al., 1994) . Incubation of T cells with these compounds strongly stimulated activity of the HTLV-I LTR, which could be further induced upon the addition of forskolin. This activation was partly CREBdependent and required most components of the TCR pathway. In addition, we identified the PTP, SHP-1, as an upstream regulator of this induction. We conclude that PTPs play an important role in the control of HTLV-I gene expression and that inhibition of this activity leads to higher levels of HTLV-I LTR activity.
Results

BpV[pic] is a powerful activator of HTLV-I LTR transcription
We have previously used strong PTP inhibitors to study the impact of tyrosine phosphorylation on gene regulation in the context of T cells (Barbeau et al., 1997; Fortin et al., 2001; Ouellet et al., 1999) . These compounds are termed bis-peroxovanadium (bpV) (Posner et al., 1994) and were demonstrated in our previous studies to strongly inhibit PTP activity in Jurkat T cells. On the basis of a previous study establishing that tyrosine phosphorylation might be required for Tax-dependent HTLV-I LTR regulation , we tested our bpV compounds in Jurkat cells to gain a better understanding of the role played by tyrosine phosphorylation in HTLV-I LTR gene expression.
Jurkat cells were transfected with an HTLV-I LTR reporter vector (pHTLV-LUC) and a wild-type Tax expression vector or the empty vector. Different combinations of activators were subsequently added to the transfected cells. As depicted in Fig. 1A , stimulation of T cells by the bpV [pic] PTP inhibitor led to a significant increase in Tax-dependent LTR activation to levels higher than those measured in untreated cells (36.7-fold). The addition of PMA with or without ionomycin led to a significant but weaker induction of Tax-dependent LTR activation. However, unexpectedly, we found that bpV[pic] also induced a potent increase in LTR gene expression in the absence of Tax expression. In fact, LTR-dependent gene expression was induced 20-fold following PTP inhibition, which was significantly greater than induction measured in cells treated with PMA alone or in combination with ionomycin (2.4 and 4.2-fold, respectively). This increase in HTLV-I LTR activity could not be generalized to all promoters as no similar induction in reporter gene expression was noted when Jurkat cells transfected with a h-actin promoter-driven h-gal vector was treated with our PTP inhibitors (data not shown).
We next conducted a time course analysis to determine the optimal time for HTLV-I LTR activation by bpV [pic] . Fig. 1B demonstrated that optimal HTLV-I LTR induction occurred at 8 h following bpV[pic] treatment, reached a plateau at 12 h, and then returned to basal level after 24 h of stimulation. Such a pattern of induction has also been observed in previous studies testing several activating agents in T cells (including PTP inhibitors) (Fortin et al., 2001; Ouellet et al., 1999) . In comparison, activation by either PMA or the PMA/ionomycin combination continued to increase after 24 h of incubation, a result which is consistent with a previous study (Mor-Vaknin et al., 1997) . Activation of the HTLV-I LTR by bpV [pic] was also detected in other T-cell lines such as SupT1 and HPB.ALL (data not shown). These results demonstrate that PTP inhibitors can independently induce activation of the HTLV-I LTR in different T-cell lines, and that this LTR activation is greater than other previously described stimulation.
Activation of the HTLV-I LTR by bpV[pic] is synergistic with forskolin
We next investigated possible synergistic activation of the LTR by bpV [pic] and other known activators of HTLV-I transcription. A series of different activators was tested individually or in combination. These included PHA, PMA, ionomycin, anti-CD3 (OKT3) and anti-CD28 (9.3) antibodies, bpV [pic] and forskolin, a compound that upregulates HTLV-I gene expression by activating the CREB transcription factor (Nakamura et al., 1989; Poteat et al., 1989) . Jurkat cells were transfected with the pHTLV-LUC vector and subsequently stimulated as indicated ( Fig. 2A) . As demonstrated earlier, bpV[pic] potently induced HTLV-I LTR-regulated gene expression while other activators resulted in poor activation. When the PTP inhibitor was combined with other activators, bpV-dependent induction was either unaltered (PMA, ionomycin, anti-CD3/anti-CD28), reduced (PMA/ionomycin) or was weakly enhanced (PHA, PHA/PMA). The greatest synergistic activation of the LTR was observed in the presence of forskolin and bpV [pic] . A similar synergistic activation of the LTR by bpV [pic] and forskolin was also observed in isolated peripheral blood mononuclear cells (PBMCs) transfected with the pHTLV-LUC vector (data not shown).
Synergistic activation of the LTR by forskolin and bpV [pic] or PMA was compared at different concentrations in Jurkat cells transfected with pHTLV-LUC (Fig. 2B) . Although a significant increase was apparent for all tested activators at higher concentrations of forskolin, the greatest synergistic induction was observed in the presence of the bpV[pic]/forskolin combination. Also, maximal synergistic activation with bpV[pic] occurred at a lower concentration of forskolin (1 AM) than needed to induce synergistic activation with PMA.
Sodium orthovanadate is another PTP inhibitor, which has been suggested to be less potent than bpV[pic] (Posner et al., 1994) . LTR activity in response to different concentrations of bpV [pic] or sodium orthovanadate in the presence or absence of forskolin was analyzed in Jurkat cells (Fig. 2C) . Sodium orthovanadate did not induce HTLV-I LTR-mediated gene expression either alone or in the presence of forskolin, indicating that bpV [pic] was likely more inhibitory for PTPs and consequently a better activator of HTLV-I LTR transcription. These results also indicated that the action of bpV[pic] occurred over a very narrow concentration range and was not measurable at 1 AM either with or without forskolin.
Since the synergy of bpV [pic] and forskolin might be driven by the ability of forskolin to activate CREB, we tested PGE 2 , another CREB activator, which we have recently shown to activate the HTLV-I LTR upon concomitant TCR activation (Dumais et al., 2003) . Jurkat cells transfected with pHTLV-LUC were treated with bpV [pic] alone or in combination with PGE 2 . As demonstrated in Fig.  2D , the combination of PGE 2 and bpV[pic] resulted in synergistic activation of the HTLV-I LTR supporting a role for CREB in bpV[pic]-mediated activation of the LTR. As we have previously demonstrated (Dumais et al., 2003) , PGE 2 alone was a poor activator of the HTLV-I LTR.
To determine whether this bpV-dependent activation of the HTLV-I LTR was reporter-dependent, the GFP reporter gene was positioned downstream of the HTLV-I LTR. Typically, less than 1% of Jurkat cells transfected with the pHTLV-GFP vector showed a positive GFP signal. In Jurkat cells co-transfected with pHTLV-GFP and the Tax expression vector, GFP signals could be detected in up to 6% of the analyzed cells (data not shown). Therefore, Jurkat cells were transfected with pHTLV-GFP and subsequently stimulated with different activating agents for 8 h. A small increase in the number of cells positive for GFP expression was observed following PMA/ionomycin treatment (1.93%) (Table 1) To evaluate bpV [pic] activation of HTLV-I LTR transcription in the context of full-length HTLV-I proviral DNA, a luciferase reporter gene was inserted in frame with the envelope ATG initiation codon from the K30 proviral DNA clone without altering the splice donor site for multiply spliced mRNA. This proviral DNA was directly transfected into Jurkat cells and the transfected cells were subsequently treated with activators. As depicted in Fig. 3A , activation by bpV [pic] and all other tested activators led to a weak induction, which was less than 2-fold. However, the combination of bpV [pic] and forskolin induced luciferase expression by 9.1-fold 8 h after stimulation, and this activity was greatly enhanced at 24 h post-stimulation (129.7-fold) and sustained up to at least 72 h post-treatment.
Previous experiments have indicated differences in the regulation of HTLV-I gene transcription when integrated into cellular DNA versus an episomal form (Lemasson et al., 2002; Okada and Jeang, 2002) . To confirm our results with integrated proviral DNA, we performed experiments with HTLV-I-infected MJ cells, which are CD3-and CD4-positive T-cells. At different time points after stimulation, supernatants from the MJ cells were quantitated for the presence of the HTLV-I p19 antigen. As illustrated in Fig.  3B , at 24 h post-stimulation, only the bpV[pic]/forskolin combination led to a significant increase in supernatantassociated p19 antigen. While bpV[pic] alone had little effect on the production of HTLV-I p19 in the supernatant of MJ cells throughout the time course, bpV[pic]/forskolin led to a sustained increase in p19 production, to higher levels than observed following treatment with the combination of PMA/ionomycin. Forskolin-like PMA had no detectable effect on the level of extracellular p19 antigen (data not shown). These results support the notion that bpV compounds can activate the HTLV-I LTR in the context of episomal DNA as well as the integrated proviral DNA form, although forskolin was required to observe this induction in MJ cells.
Effect of early TCR-like cell signaling mediated by bpV compounds on HTLV-I LTR activation
Our results confirmed that TCR-mediated T cell activation results in weak activation of the HTLV-I LTR. Since PTP inhibitors can activate multiple transcription factors through TCR-like events (Ouellet et al., 2003a,b) , we next examined the effect of bpV[pic] on the activation of HTLV-I LTR transcription in response to TCR signaling pathways. To determine whether the T-cell receptor is required for activation of HTLV-I LTR transcription by bpV[pic], both Jurkat and J.RT3 (a TCR-negative derivative) cells were transfected with the pHTLV-LUC reporter construct and transfected cells were then exposed to various agents. bpV[pic]-mediated LTR activation (with or without added forskolin) was decreased in J.RT3 cells as compared to Jurkat cells, although a significant induction of the HTLV-I promoter was still observed in J.RT3 cells (Fig. 4A ). Other activating agents showed similar abilities to activate the LTR in both Jurkat cell lines. These results suggest that the TCR is not absolutely necessary for bpV[pic] induction of HTLV-I LTR-mediated gene expression and agree with our observation of HTLV-I LTR activation in the TCR-negative SupT1 cell line (data not shown).
ZAP70 is another important player in T cell signaling. P116 cells are Jurkat cell derivatives that are negative for ZAP70 (Williams et al., 1998) . A stable transfectant (P116 clone 39) has been generated from this clone and expresses normal levels of ZAP70. P116, P116 clone 39, and Jurkat cells were transfected with pHTLV-LUC and then stimulated with the different activators (Fig. 4B) .
Comparison of the different cell lines showed that P116 cells had the weakest HTLV-I LTR response to bpV [pic] . P116 clone 39 showed an increased HTLV-I LTR response to bpV stimulation and reached levels of activation close to that observed in similarly stimulated and transfected Jurkat cells. ZAP70 expression was also required for activation of the HTLV-I LTR by the bpV[pic]/forskolin combination. In general, activation by PMA, PMA/ ionomycin or forskolin was not statistically different in the presence or absence of ZAP70. This was expected due to the fact that these agents activate the signaling pathway downstream of ZAP70. Since the calcineurin serine/threonine phosphatase plays an important role in activating several transcription factors in T cells, we assessed the effect of this serine/threonine phosphatase on bpV[pic]-mediated HTLV-I LTR activation. Jurkat cells transfected with the pHTLV-LUC vector were treated with FK506 or CsA, two specific calcineurin inhibitors, prior to stimulation (Fig. 4C) . Both of these inhibitors reduced the capacity of bpV [pic] and bpV[pic]/ forskolin activators to induce HTLV-I LTR activity. Since calcium is a crucial signaling mediator in the activity of calcineurin, we assessed the role of intracellular calcium mobilization in bpV[pic]-dependent activation of the HTLV-I LTR. PMA/ionomycin activation of the HTLV-I LTR was reduced in the transfected CJ1.1 cell line, deficient for capacitative calcium entry, as compared to the wild type CJ parental clone (Fig. 4D) . Importantly, a similarly reduced LTR response was observed in this calcium-deficient cell line when cells were stimulated with the PTP inhibitor (with or without forskolin), suggesting that calcium plays an important role in activation of the HTLV-I LTR by PTP inhibition. These results demonstrate that certain cellular components involved in TCR-mediated signaling play a role in the bpV[pic]-mediated signaling cascade that leads to HTLV-I LTR activation. However, the TCR was not specifically required in this pathway.
BpV[pic] activation of HTLV-I LTR activity is counteracted by SHP-1 expression
Activation of the HTLV-I LTR by the PTP inhibitor suggested the involvement of one or more PTPs in this activation pathway. We looked at the possible role of two important PTPs, CD45 and SHP-1, initially focusing on CD45 as a target of bpV [pic] . JKF cells and the CD45-deficient K6D cell line derived from JKF cells were transfected with pHTLV-LUC and subsequently treated with the activating agents. No significant differences in LTR response to any of the tested activators including bpV [pic] were detected (data not shown). The Jurkatderived CD45-negative J45.01 cell line was also compared to Jurkat cells, and again no significant difference in response was observed when cells transfected with pHTLV-LUC were treated with our PTP inhibitor (data not shown). We then turned our attention to SHP-1. This PTP is required to terminate the TCR-initiated cascade and has been observed to dephosphorylate several crucial players in this cascade. To determine whether SHP-1 was targeted by bpV[pic], a vector expressing SHP-1 or the empty vector were co-transfected with pHTLV-LUC into Jurkat cells and cells were then stimulated with the different activators (Fig. 5) . We predicted that overexpression of a PTP targeted by bpV [pic] should block activation of the HTLV-I LTR. In fact, although SHP-1 expression did not affect the response of the HTLV-I LTR following PMA or PMA/ionomycin induction, its expression significantly reduced bpV[pic]-and bpV[pic]/forskolin-dependent HTLV-I LTR activation. These results thus suggest that SHP-1 inhibition might be responsible for activation of the HTLV-I LTR following bpV[pic] treatment.
Role of the LTR region containing TRE1 sequences in bpV[pic]-mediated activation of the HTLV-I transcription TRE1 sequences in the HTLV-I LTR contain CREBbinding sites that are important for positive regulation of HTLV-I transcription. To determine the potential role of these sequences in bpV-mediated LTR activation, LTR deletion mutants were generated with or without the TRE1 sequences. These constructs were transfected into Jurkat cells and, after cell activation, extracts were prepared and luciferase activity was quantitated (Fig. 6A) . Removal of the 5V LTR sequence up to position À325 (pHTLV-LUCDSmaI) did not significantly alter LTR activation by any of the tested activators including bpV [pic] . However, deletion up to position À57, which removed all three TRE1 sequences, completely abolished activation mediated by bpV either alone or in the presence of forskolin. To confirm the importance of the sequence contained between position À325 and À57, the SmaI/NdeI fragment (harboring all 3 TRE1s) was cloned upstream of a minimal promoter (TATA box) and the luciferase reporter gene (pGL2tata HTLV(À325/À57)). BpV[pic] treatment of Jurkat cells transfected with this construct resulted in a significant induction of luciferase activity that was absent in cells transfected with the pGL2tata control vector (Fig. 6B and  data not shown) . Interestingly, the activation was more pronounced than the one measured with the pHTLV-LUC construct. In fact, in Jurkat cells, a significant response of the pGL2tata HTLV(À325/À57) construct was observed following treatment with forskolin, PMA, or PMA/ionomycin. Similar transfection results in Jurkat cells were obtained when the HTLV-I TRE1-containing cassette was positioned upstream of the SV40 promoter and the luciferase reporter gene (pGL2-Promoter HTLV(À325/À57)) (data not shown). These results suggest that the TRE1 sequences play an important role in activation of the HTLV-I LTR mediated by bpV [pic] .
Role of a CREB/ATF family member in HTLV-I LTR activation induced by bpV[pic]
Since CREB is an important positive modulator of the HTLV-I LTR TRE1 sequences, we tested its potential role in modulation of HTLV-I LTR activity by bpV[pic]. To These results suggest that a member of the CREB transcription factor family is required for bpV [pic] activation of the HTLV-I LTR. To confirm the involvement of a CREB/ ATF member, cells were treated with increasing subcytotoxic concentrations of MDL-12,330A, an adenylate cyclase inhibitor, which thus diminishes the level of intracellular cAMP. Jurkat cells transfected with pHTLV-LUC were less responsive to bpV [pic] or bpV[pic]/forskolin stimulation upon MDL-12,330A treatment, dropping to 40% to 45% from fold activation levels measured in untreated cells, while limited effect was noted on PMA/Ionomycin-activated cells. Forskolin was also sensitive to this inhibitor while PMA-stimulated cells were not affected (data not shown). To further demonstrate that bpV[pic] activated a member of the CREB/ATF family, Jurkat cells were transfected with pCRE-LUC, which contains 4 tandem repeats of the CRE element (Fig. 7C) . Upon activation of the transfected Jurkat cells, reporter gene expression was responsive to several stimulating agents. While forskolin and bpV[pic] both activated this reporter weakly, forskolin alone was a more potent activator of CREB-dependent transcription than bpV[pic] alone. However, the combination of bpV[pic]/ forskolin again led to a significant increase in CREBdependent luciferase expression. As expected, PMA and PMA/ionomycin were poor inducers of luciferase gene expression in these transfected cells.
We directly tested the possible role of CREB family members in activation of the HTLV-I LTR by bpV [pic] by overexpressing the ATF/CREB family member in Jurkat cells. Expression vectors for wild type CREB or a constitutively active version of CREB were transfected into Jurkat cells along with pGL2tata HTLV(À325/À57) and then stimulated with different activators (Fig. 7D ). To our surprise, expression of wild type or constitutively active CREB resulted in a significant reduction in the activation of pGL2tata HTLV(À325/À57) by bpV [pic] or bpV[pic]/ forskolin, while no comparable effects were observed in PMA/ionomycin-stimulated cells. As a control, Jurkat cells were similarly co-transfected with the CREB expression vectors and pNF-nB-LUC (Fig. 7E) . In contrast to the results presented above, CREB expression had no effect on NF-nB-dependent luciferase expression regardless of the tested activator. This result is likely due to competitive binding of the overexpressed CREB protein to the LTR, thereby displacing a functional CREB family member. It appears unlikely that the reduced HTLV-I LTR activity observed upon CREB expression and bpV [pic] treatment is simply an effect of squelching the CBP/p300 co-activators since a similar effect was not observed on a NF-nB dependent promoter. Together, these results suggest that a CREB family member, but not CREB itself, is involved in bpV[pic]-mediated activation of the HTLV-I LTR.
A second factor is required for bpV-induced HTLV-I LTR activity
To more directly address the role of TRE1 CREBbinding sites in activation of the HTLV-I LTR following PTP inhibition, different HTLV-I LTR constructs containing mutations in 1, 2, or all 3 TRE1 repeats were used (Fig. 8A) . Reduced bpV [pic] activation was reproducibly observed when these constructs were transfected into Jurkat cells and was most evident when all three TRE1 sequences were mutated (Fig. 8B) . However, even in this triple TRE1-mutated construct (pGL3-21PMD/11T), a significant level of bpV-dependent activation was still apparent and accounted for more than 50% of the activity observed with the wild-type LTR. A similar trend was detected with the bpV[pic]/forskolin combination. PMA and PMA/ionomycin induced luciferase gene expression to similar levels for all 8 tested LTR constructs. In contrast to these results, cotransfection of a Tax expression vector with pGL3-21PMD/ 11T showed a greater than 90% reduction in luciferase expression from that observed on pGL3-U3R at both 24 and 48 h post-transfection (Fig. 8C) . These data are consistent with the idea that activation of the HTLV-I LTR by bpV [pic] is not exclusively dependent on the CREB-binding elements located in the TRE1 repeats.
Discussion
In this study, we were interested in assessing the involvement of PTP in the transcriptional regulation of HTLV-I. A previous study had suggested that tyrosine phosphorylation plays an important role in HTLV-I transcription by the Tax protein combined with a PHA stimulation . Indeed, in this study, we demonstrated that the use of a PTP inhibitor termed bpV [pic] , which is known to increase intracellular phosphotyrosine levels, resulted in a significant increase in HTLV-I LTR activity.
Our first experiments were conducted to assess the role of bpV [pic] in Tax-mediated LTR activation. These results indicated that bpV[pic] could significantly induce HTLV-I LTR activity in both Tax-expressing and non-Tax-expressing cells. Time course experiments permitted us to conclude that this induction was likely mediated by direct activation of a signaling pathway since the optimal effect was at 8 h, consistent with several studies from our group using different activators that act directly on specific transcription factors such as NFAT and NF-nB (Barbeau et al., 1997; Fortin et al., 2001; Ouellet et al., 1999) . In addition, the kinetic response of the HTLV-I LTR induced by bpV [pic] was drastically different (at least in Jurkat cells) from the activation pattern of PMA, recently linked to apoptosis (Torgeman et al., 2001a) . These results with bpV [pic] demonstrate the potential of TCR-like signaling cascades to positively modulate HTLV-I gene expression.
A series of experiments also indicated that the combination of forskolin and bpV [pic] resulted in increased activation of the HTLV-I LTR, while other agents in combination with bpV[pic] generally did not affect the bpV[pic] response. In contrast, sodium orthovanadate had no such effect, which is consistent with the fact that bpV compounds are more efficient PTP inhibitors than sodium orthovanadate. It is also possible that bpV compounds might target different PTPs than those inhibited by sodium orthovanadate. In the presence of bpV [pic] , forskolin efficiently induced the HTLV-I LTR to greater levels than PMA. Similar to bpV[pic] (discussed below), PHA and PMA are likely to be weak activators of CREB and might also activate other HTLV-I-regulatory factors that synergize with CREB. This is consistent with our finding that bpV[pic] strongly synergizes with PGE 2 , another CREB activator, to regulate the HTLV-I LTR. We have previously described a synergism between PGE 2 and antigen-like stimulation, which appears to use a similar mechanism to activate the HTLV-I LTR (Dumais et al., 2003) .
In light of previous publications addressing the transcriptional regulation of integrated HTLV-I DNA (Lemasson et al., 2002; Okada and Jeang, 2002) , we also investigated the modulation of HTLV-I replication in HTLV-I-infected cells following stimulation. We found a significant increase in viral particle production as determined by p19 antigen levels following bpV[pic] treatment in the presence of forskolin. Furthermore, transient transfection of a proviral DNA construct containing the luciferase reporter gene confirmed that activation of the HTLV-I LTR in the context of proviral DNA was also observed in cells treated with forskolin and bpV [pic] . This activation occurred at later time points than similarly treated pHTLV-LUC-transfected cells. The multiple splicing events that are required for expression of viral gene products likely contributed to the delay in detecting peak viral replication responses to PTP inhibition. BpV [pic] , as well as other activators added alone, resulted in poor activation of the HTLV-I LTR in the context of proviral DNA. Although this result requires further investigation, it is possible that the negative regulatory functions of the viral HBZ and p30 II proteins could contribute to the lack of response to these activators (Gaudray et al., 2002; Nicot et al., 2004) . Despite this caveat, the above results do suggest that PTPs may influence HTLV-I gene expression in vivo.
BpV compounds have been previously shown to utilize signaling pathways similar to those induced by the TCR Luciferase values were reported as the mean value of triplicates F SD. Fold inductions were calculated as the ratio of the mean value of treated samples over the mean value of untreated samples. (C) Jurkat cells were co-transfected with 10 Ag of the Tax expression vector (or the empty pHhPr.1-neo vector) and 10 Ag of either pGL3-U3R or pGL3-21PMD/11T. Cells were lysed 24 or 48 h after transfection and luciferase activity was assessed. Luciferase values were reported as the mean of triplicates F SD. Fold inductions were calculated as the ratio of the mean value of Tax-transfected cells over the mean value of empty vectortransfected cells. These results are representative of three independent experiments. (Fortin et al., 2001; Ouellet et al., 1999 Ouellet et al., , 2003a . Activation of the HTLV-I LTR by these inhibitors was not surprisingly found to depend on ZAP70, calcineurin activity and calcium mobilization, but did not require the expression of cell surface TCR. These signaling molecules are also involved in bpV-mediated NF-nB and NFAT activation (Fortin et al., 2001; Ouellet et al., 1999) . These results support the idea that TCR signaling can activate the HTLV-I LTR. This is especially relevant since our data suggest that the PTP targeted by bpV [pic] , permitting activation of the HTLV-I LTR, is likely to be SHP-1, a crucial downregulator of TCR signaling.
Our results strongly suggest that the TRE1 repeats are important for PTP-dependent activation of the HTLV-I LTR. Indeed, isolated TRE1 sequences were sufficient to confer bpV [pic] responsiveness to a minimal promoter. We also suggested that CREB activation and binding to the CREBbinding site within the TRE1 repeats is important for activation of HTLV-I transcription. Furthermore, point mutation of the CREB-binding site in all three TRE1 repeats reduced the ability of the PTP inhibitor to induce transcription. Parallel experiments conducted with the pCRE-LUC plasmid also showed that it was activated by bpV [pic] in synergy with forskolin. The ability of our PTP inhibitors to activate CREB/ATF family members is not surprising in light of a previous study indicating that PTP activity inhibits CREB activation (Champion-Arnaud et al., 1991) . It is interesting to note the difference between activation of the CREB consensus sequence (pCRE-LUC) and the CREB-binding site in the TRE1 sequence by the combination of bpV [pic] and forskolin. These dissimilar responses might reflect a minimal involvement of CREB in activation of the HTLV-I LTR following PTP inhibition (see below). We are presently making efforts to identify the CREB/ATF family member involved in HTLV-I LTR activation by bpV [pic] , and our results suggest that CREB itself is not a likely candidate. Indeed, Tax-mediated modulation of HTLV-I gene expression was affected by CREB expression in a manner similar to that observed with bpV[pic]-dependent stimulation of the HTLV-I LTR (Gachon et al., 1998) . It is tempting to speculate that CREB2 might be the relevant factor, although experiments conducted with a CREB2 expression vector indicated no increasing effects by this family member on our observed bpV-mediated induction of HTLV-I LTR activity in Jurkat cells (data not shown). Other family members are known to bind to the TRE1 regions in vivo (Lemasson et al., 2002) and might thus be involved.
Our results strongly argue for the involvement of a transcription factor that binds outside of the CRE-like consensus sequence. Based on experiments using the TRE1-mutated HTLV-I LTRs, this putative factor appears to contribute more than 50% of the induction mediated by bpV [pic] . In the presence of forskolin, bpV[pic] induction was more sensitive to the mutated TRE1 repeats, which might be expected given the known activation of CREB by forskolin. In fact, the synergy between bpV[pic] and forskolin is consistent with the weak CREB activating potential of bpV [pic] alone and strong enhancement of the CREB activating potential by forskolin. There are several possible candidates for the identity of this other factor. First, the TRE2 sequence harbors a binding site for the GLI2 protein, which was initially suggested to be involved in Taxmediated activation of the HTLV-I LTR (Dan et al., 1999; Tanimura et al., 1998) . When the LTR was mutated to knock out the GLI2-binding site in TRE2, there was no apparent difference in response of the mutant and wild-type LTRs to bpV [pic] stimulation (B.A. and B.B., unpublished results) . This suggests that GLI2 is not involved in the activation of the LTR by bpV [pic] . Previous studies have shown that PMA is a good activator of HTLV-I LTR transcription and that this activation depended on a region containing Sp1-and p53-binding sites (Torgeman et al., 2001b) . PTP inhibitors might activate these factors; however, the effect of PMA is believed to increase with time and to be enhanced by PKC inhibition. This type of kinetic activation was not observed for our PTP inhibitor, although these results do not completely rule out the possible involvement of these factors in bpV[pic]-mediated activation of HTLV-I transcription. Since other transcription factor-binding sites (including the recently described serum response element (Wycuff et al., 2004) ) have been identified within the HTLV-I LTR, further studies will be needed to identify the transcription factor that mediates bpV [pic] activation of the HTLV-I LTR.
The data presented in this study argues that constitutive expression of various cellular PTPs provide an important mechanism to suppress HTLV-I transcription in infected cells thereby contributing to their immune escape. It remains possible that an increase in oxidative state might also be induced through the peroxo group of the bpV[pic] compound as described previously (Baier-Bitterlich et al., 1996; Sasada et al., 2002) , and could partially contribute to activation of the HTLV-I LTR. However, our analysis of the signaling pathway activated by bpV [pic] suggests that the main mechanism behind the modulation of HTLV-I gene expression by bpV [pic] involves the inhibitory potential of PTP activity. PTP inhibition (possibly by SHP-1) provides a possible mechanism for activation of latent HTLV-I proviral DNA. In fact, it has been shown that HTLV-I-infected cells are frequently negative for SHP-1 expression (Cheng et al., 2004; Migone et al., 1998) , although the absence of SHP-1 expression is also observed in other leukemic cell lines and is thus not exclusive to HTLV-I-infected transformed cells. Since it has been suggested that activation of HTLV-I gene expression might be sudden and dependent on cell-to-cell contact, PTP inhibition could potentially turn on a signaling cascade, resulting in rapid turn on of viral gene expression, viral particle production and transmission to uninfected cells.
Our results indicate a strong transcriptional upregulation of the HTLV-I LTR by the bpV[pic] PTP inhibitor in T cells.
The implication of PTP inhibition in positive regulation of the HTLV-I gene transcription needs to be further addressed with respect to key events in HTLV-I replication such as HTLV-I transmission to uninfected cells. We are presently addressing these issues to better identify the transcription factors involved in bpV-dependent modulation of HTLV-I transcription.
Materials and methods
Cell lines and PBMCs
Jurkat (clone E6-1) (Weiss et al., 1984) , and Jurkatderived J45.01 (Koretsky et al., 1991) , J.RT3 (Morley et al., 1988) and P116 (Williams et al., 1998) cell lines were included in this study. J45.01 (generously provided by Dr. Arthur Weiss, Howard Hughes Medical Center San Francisco, CA), J.RT3 and P116 (kindly given by Dr. Robert T. Abraham, The Mayo Clinic Rochester, MN) are deficient in CD45, TCR and ZAP70/Syk expression, respectively. P116 clone 39 was derived from P116 and has been recomplemented for ZAP70 expression. Jurkat derivatives deficient in a mode of calcium entry dependent on extracellular calcium known as capacitative calcium entry (CJ.1) and the parental CJ clone (Fanger et al., 1995) were kindly provided by Dr. Richard S. Lewis (Stanford University School of Medicine, Stanford, CA). The CD45-negative K6D cell line has been previously described and is a clone derived from the JKF cell line stably expressing antisense CD45 mRNA (McKenney et al., 1995) . The HPB.ALL cell line (Koretsky et al., 1990 ) is a TCR-positive T cell line with a more immature phenotype than Jurkat cells and was generously provided by Dr. Arthur Weiss. The SupT1 T-cell line (Smith et al., 1984) is negative for the TCR and was obtained from the NIH AIDS Repository Reagent Program (Rockville, MD). The HTLV-I-infected MJ cell line (Popovic et al., 1983) produces infectious particles and was purchased from the American Type Culture Collection (Manassas, VA). Cell lines were maintained in RPMI-1640 medium supplemented with 10% FBS (Hyclone Laboratories, Logan, UT), glutamine (2 mM), penicillin G (100 U/ml), and streptomycin (100 Ag/ml). G418 (Invitrogen Life Technologies, Burlington, Canada) and Hygromycin B (Calbiochem, San Diego, CA) were added to the appropriate concentrations as indicated. PBMCs from healthy donors were isolated by Ficoll-Hypaque density gradient centrifugation as previously described (Fortin et al., 1999) .
Plasmid constructs
The pHTLV-LUC vector (Geleziunas et al., 1998) was kindly provided by Dr. Warner C. Greene (The J. Gladstone Institutes, San Francisco, CA) and contains the HTLV-I LTR cloned upstream of the luciferase reporter gene in the pGL2-Basic vector (Promega, Madison, WI). The pHTLV-GFP construct was generated by excising the luciferase gene/ poly(A) segment from pHTLV-LUC and inserting a green fluorescent protein (GFP)/SV40 poly(A) fragment isolated from the HindIII/BamHI-digested phGFP-S65T vector (BD Biosciences Clontech, Palo Alto, CA). Deletion mutants of pHTLV-LUC were generated by self-ligation after digestion with SmaI (pHTLV-LUCDSmaI) or SmaI and NdeI (pHTLV-LUCDNdeI/SmaI). The pGL2tata-LUC vector was constructed by subcloning a synthetic double-stranded oligonucleotide containing a TATA box and extremities compatible with NheI/HindIII (produced from hybridized 5V-CTAGCGGGTATATAATGGATCCA-3V and 5V-AGCTTG-GATCCATTATATACCCG-3V oligonucleotides) into the digested pGL2-Basic vector (Promega). The pGL2tata HTLV(À325/À57) construct was then generated by cloning the SmaI/NdeI blunted fragment from the HTLV-I LTR into the SmaI site of the pGL2tata-LUC vector. A similar cloning procedure was used to insert this HTLV-I LTR fragment into the SmaI-digested pGL2-Promoter vector (Promega) generating pGL2-Promoter HTLV(À325/À57). Constructs were also created with previously described HTLV-I LTRs (Barnhart et al., 1997) being either wild type or mutated for one, two, or all three CREB consensus sequences located in the TRE1 regions. These LTRs were excised from their vector by XhoI/HindIII and cloned into the pGL3-Basic vector (Promega) using the same restriction site. These vectors are termed pGL3-U3R, pGL3-21P/11T, pGL3-21M/ 11T, pGL3-21D/11T, pGL3-21PM/11T, pGL3-21PD/11T, pGL3-21MD/112T and pGL3-21PMD/11T, and are wild type or mutated in the proximal (P), middle (M) and/or distal (D) TRE1 sequences. Expression vectors for the wild type Tax protein and the empty vector (pHhPr.1-neo) (Matsumoto et al., 1997) were kindly provided by Dr. Masataka Nakamura (Tokyo Medical and Dental University, Tokyo, Japan). The pNF-nB-LUC and pCRE-LUC vectors were obtained from Stratagene (La Jolla, CA) and contain multiple NF-nB-and CREB-binding sites, respectively, positioned upstream of a minimal promoter and the luciferase reporter gene. Vectors encoding wild-type SHP-1 as well as the empty vector pSFFVneo (Plas et al., 1996) were provided by Dr. Matthew L. Thomas (Washington University School of Medicine, Saint Louis, MI). The CREB dominant negative mutant KCREB and the control empty vector (Walton et al., 1992) were provided by Dr. R.H. Goodman (Vollum Institute for Advanced Biochemical Research, Portland, OR). Vectors expressing wild type CREB or the constitutively active CREB F/Y mutant (Du et al., 2000) were obtained from Dr. Marc Montminy (The Salk Institute for Biological Studies, La Jolla, CA). We constructed the empty vector termed pcDNA.CF by selfligation after excision of the insert.
Generation of luciferase-containing HTLV-I proviral DNA
The 5VK30-Luc vector was derived from the previously described K30 plasmid harboring a full-length and infectious HTLV-I proviral DNA clone (Zhao et al., 1995) obtained from the NIH AIDS Repository Reagent Program. A BamHI fragment was isolated from this construct (position 5102 to 6107) and cloned into pBlueScript SK (Stratagene). This fragment contained the ATG initiation codon for the env, tax, and rex genes. A two-step PCR mutagenesis protocol directed at position 5550 to 5552 (48 nucleotides downstream of the ATG codon) mutated the ATC sequence to GAG thereby generating a SacI site. Briefly, the 5V-CAGTTCTGCCCCCTCGAGCTCGGTGATTACAGCCC-CAG-3V/Reverse primer and 5V-CTGGGGCTGTAAT-CACCGAGCTCGAGGGGGCAGAACTG-3V/Universal primer combinations were used for amplification of 5V and 3V ends of the BamHI fragment. Both amplified products were mixed and amplified as a complete fragment with pBlueScript Reverse and Universal primers. The luciferase gene was amplified from pGL3basic with oligonucleotides (5V-TGGAGCTCGTTGGTAAAGCCACCATGGAA-GACGCCAAAAAC-3V and 5V-ACGAGCTCATCAATG-TATCTTATCATGTCTGCTCGAAGC-3V) to generate SacI sites at each end, and then cloned in frame with the HTLV-I ATG codon into the SacI-generated site of the K30 BamHI fragment. Sequencing of each PCR-amplified product was carried out to ascertain proper sequence. The BamHI fragment was subsequently cloned into the K30 vector, after BamHI digestion, to generate 5V K30-LUC. Since the 3V end of the K30 proviral DNA had been deleted in this construct, complete full-length proviral DNA was recreated by ligating this 5V K30 end (EcoRI/ SalI digestion) with the 3V K30 fragment (SalI/EcoRI). The ligation mixture was then directly transfected into T cell lines.
Antibodies and reagents
BpV[pic] was synthesized as previously described (Posner et al., 1994) and supplied by Dr. R. Faure (CHUL Research Center, Ste-Foy, Canada). Briefly, V 2 O 5 was dissolved in an aqueous KOH solution and then mixed with 30% H 2 O 2 and the picolinic acid ancillary ligand in addition to ethanol for optimal precipitation. Characterization of the bpV molecule was carried out by infrared 1 H NMR and vanadium-51 ( 51 V) NMR spectroscopy. Stock solutions of bpV[pic] molecules (1 mM in phosphatebuffered saline, pH 7.4) were kept at À20 8C until used. Sodium orthovanadate (Sigma, St Louis. MO) was freshly dissolved in 10 mM HEPES, pH 7.4. FK506 and cyclosporin A (CsA) were purchased from Fujisawa (Osaka, Japan) and Sigma, respectively. Antibodies from the anti-CD3 OKT3 hybridoma were purified with mAbTrap protein G affinity columns (Pharmacia LKB Biotechnology AB, Uppsala, Sweden). Purified anti-CD28 antibodies (clone 9.3) were provided by Dr. Jeffrey A. Ledbetter (BristolMyers Squibb Pharmaceutical Research Institute, Princeton, NJ).
Transfections and reporter gene assays
Transient transfections of T-cell lines using the DEAEDextran method were performed as previously described (Barbeau et al., 1997) . Electroporation of PBMCs was conducted according to Hughes and Pober's protocol (Hughes and Pober, 1996) . Transiently transfected cells were seeded at a density of 10 5 cells/well in 96-well plates and left unstimulated or treated for 8 h (unless specified) with bpV[pic] (10 AM), PHA-P (3 Ag/ml), PMA (20 ng/ml) (Sigma), ionomycin (1 AM) (Iono; Calbiochem), anti-CD3 antibody (clone OKT3) (3 Ag/ml), anti-CD28 antibody (clone 9.3) (1 Ag/ml), forskolin (100 AM) (BioMol, Plymouth Meeting, PA) and prostaglandin E 2 (100 nM) (PGE 2 ; Sigma) in a final volume of 200 Al. For some experiments, prior to activation, cells were treated with FK506 (10 ng/ml) or CsA (100 ng/ml) for 15 min or with MDL-12,330A (100-250 AM) (Calbiochem) for 1 h at 37 8C. Cells were then lysed in a 1Â lysis buffer (25 mM Tris phosphate, pH 7.8, 2 mM DTT, 1% Triton X-100, 10% glycerol). Luciferase activity was determined as follows. After a freeze/thaw cycle, 20 Al of cellular extract was transferred to a 96-well luminometer plate, and luciferase activity was quantitated on a Dynex MLX microplate luminometer (MLX; Dynex Technologies, Chantilly, VA) following the addition of 100 Al of luciferase buffer (20 mM tricine, 1.07 mM (MgCO 3 ) 4 d Mg(OH) 2 d 5 H 2 O, 2.67 mM MgSO 4 , 0.1 mM EDTA, 220 AM Coenzyme A, 4.7 AM d-Luciferin potassium salt, 530 AM ATP, 33.3 mM DTT). Values from the luminometer are expressed as Relative Light Units (RLU). Fold induction was calculated as the ratio between the mean values F standard deviation (SD) of the luciferase activity of treated over untreated samples. Cells transfected with the pHTLV-GFP vector were fixed in a solution of 1Â phosphate-buffered saline (PBS) containing methanol-free 1% paraformaldehyde and subsequently analyzed by flow cytometry for GFP detection (EPICS XL, Coulter Corp., Miami, FL).
Detection of supernatant HTLV-I p19 antigen
HTLV-I-producing MJ cells (1 Â 10 6 cells/ml) were treated with PMA (20 ng/ml)/ionomycin (1 AM), bpV [pic] (10 AM) and bpV[pic] (10 AM)/forskolin (100 AM). Supernatants were subsequently harvested at 24, 48, and 72 h post-activation. Quantification of HTLV-I p19 antigen in the collected supernatant was performed using an ELISA HTLV-I p19 antigen kit (Zeptometrix, Buffalo, NY) as described by the manufacturer. 
